Sarepta Therapeutics has penned its second DMD gene therapy pact this year.

Syntimmune has got off a beefy $50 million series B round.

German Merck and R&D charity CRUK are coming together to launch a biotech focused on immuno-oncology.

EvaluatePharma has totted up the figures for R&D spend and costs for biopharmas, and the figures are huge.

Filings for brolucizumab are expected next year, with analysts at Jefferies predicting $2 billion in peak sales for the drug.

Gamida Cell has upped its financing by $40 million in its latest funding round to prep for final work on a late-stage stem cell blood cancer therapy.

Sean Parker’s immuno-oncology institute has allied with Tessa Therapeutics to turn T-cell therapies against solid tumors.

An Ernst & Young report shows a mixed bag across the whole sector.

Bavarian Nordic has again delayed the release of data from a phase 3 trial of Prostvac.

J&J has unveiled another clutch of deals and collaborations with industry and academia.

R&D